healthevidencedigest https://validator.w3.org/feed/docs/rss2.html Transaction Failed 365 Injections a Year, or 52. A New FDA Approval Gives Families With Achondroplasia a Meaningful Choice. At a Moment When Federal Cancer Funding Is Being Cut Sharply, the ACS Just Invested in the Next Generation of Researchers. Here’s What That Means. Order History The FDA Just Rewrote the Hormone Therapy Label. Twenty-Three Years After a Study Scared Women Away From Treatment, Here’s What Actually Changed — and What Didn’t. Foundayo Was Approved in 50 Days. Now the FDA Wants a Decade of Safety Follow-Up. Here’s What’s Actually Being Studied — and Why. A Rare Cancer With No Good Options Gets a New Investigational Path. What the FDA’s Orphan Drug Designation for Eftilagimod Alfa Actually Signals. Confirmation The Number One Reason Parents Don’t Use Epinephrine in Time Is Fear of the Needle. neffy® Just Got Cleared for More Young Children. Younger Endometrial Cancer Survivors Face Years of Unnecessary Suffering. New Evidence Says One Treatment Has Been Wrongly Withheld. Eight Years, No Treatment. The UX111 Sanfilippo Gene Therapy Is Now One Step From Approval — and the Data Behind It Is Remarkable. She’s 28 and in Menopause. Two-Thirds of Women Like Her Aren’t Getting the Treatment That Could Protect Their Heart, Bones, and Brain. Products Tavneos (Avacopan) and Serious Liver Injury: What Patients and Clinicians Need to Know — Including What the FDA Isn’t Saying Publicly Checkout Receipt The FDA Just Set New Rules for CRISPR Safety Testing. Here’s Why That Matters — and What It’s Actually Asking For. Wegovy HD: The FDA Just Approved a Semaglutide Dose Three Times Stronger Than Before. Here’s What the Data Actually Shows. Hands. Grip. Independence. What the FDA’s Clearance of the ExaStim® System Actually Means for Spinal Cord Injury Rehab. That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal. AVLAYAH Approved: For Hunter Syndrome Families, This FDA Decision Hits Different Welcome to Health Evidence Digest FDA Updates Its Review of GLP‑1 Medicines and Reports of Suicidal Thoughts Resources Rocket Pharmaceuticals Secures FDA Approval for KRESLADI™, a Landmark Gene Therapy for Severe LAD‑I About FDA Requires Warning About Vitamin B6 Deficiency and Seizures in Parkinson’s Medications Teva Accelerates Its Biosimilar Strategy With New FDA Approval and Dual Global Filings FDA Approves Foundayo (Orforglipron), the First Once‑Daily GLP‑1 Pill for Weight Loss FDA Approves Corcept’s Lifyorli™ for Platinum‑Resistant Ovarian Cancer FDA Approves First Once‑Weekly Basal Insulin for Type 2 Diabetes Privacy Policy Terms of Use FDA Approves ICOTYDE™ (icotrokinra) for Moderate to Severe Plaque Psoriasis Contact Disclaimer FDA Issues Complete Response Letter for Replimune’s RP1: What the Decision Means for This Oncolytic Immunotherapy